Yes, only when this does not impact on the system’s ability to recruit participants and/or provide the resources (including staff, samples and data) needed to support nationally prioritised research.  A group, chaired by the Clinical Director for R&D, reviews all COVID-19 pipeline studies and decisions are taken as to whether to proceed or not. The final decision rests with the Clinical Director for R&D.